Evaluation in humans of a new, inactivated vaccine for Venezuelan equine encephalitis virus (C-84).

A new, formalin-inactivated vaccine for Venezuelan equine encephalitis (VEE) virus (C-84), prepared from an attenuated vaccine strain of virus (TC-83), was tested in humans. Only occasional, mild, local and systemic reactions were noted in 28 volunteers; no meaningful changes in clinical laboratory values occurred. The vaccine augmented preexisting titers of serum neutralizing antibody to VEE virus in seropositive recipients of TC-83 vaccine, and it induced high titers of neutralizing antibody in nonimmune subjects after one primary and two booster vaccinations. Circulating antibody persisted for at least 14 months in these persons. The neutralizing antibody produced after one dose of C-84 vaccine in immune subjects and after booster doses in nonimmune subjects had broad cross-reactivity within the VEE virus complex. The C-84 vaccine induced a VEE virus-specific lymphocyte transformation response. The vaccine was safe, and immunologic results showed it to be highly antigenic in healthy immune and nomimmune adults.

[1]  J. Sever,et al.  Congenital cerebral and ocular malformations induced in rhesus monkeys by Venezuelan equine encephalitis virus. , 1977, Teratology.

[2]  D. Burke,et al.  Persistence in humans of antibody to subtypes of Venezuelan equine encephalomyelitis (VEE) virus after immunization with attenuated (TC-83) VEE virus vaccine. , 1977, The Journal of infectious diseases.

[3]  P. Askenase,et al.  Basophils in tuberculin and "Jones-Mote" delayed reactions of humans. , 1976, The Journal of clinical investigation.

[4]  M. Ascher,et al.  Specific in vitro lymphocyte transformation with Venezuelan equine encephalitis virus. , 1976, Cellular immunology.

[5]  J. Turk,et al.  Mechanisms involved in the expression of Jones-Mote hypersensitivity. I. Passive cell transfer studies. , 1975, Cellular immunology.

[6]  J. Turk,et al.  B-cell suppression of delayed hypersensitivity reactions , 1974, Nature.

[7]  G. Eddy,et al.  Inactivated Venezuelan equine encephalomyelitis vaccine prepared from attenuated (TC-83 strain) virus. , 1974, Applied microbiology.

[8]  D. Martin,et al.  Venezuelan equine encephalitis. , 1974, Advances in veterinary science and comparative medicine.

[9]  V. Pinn,et al.  Cutaneous basophil hypersensitivity. IV. The "late reaction": sequel to Jones-Mote type hypersensitivity. Comparison with rabbit Arthus reaction. Effect of passive antibody on induction and expression of Jones-Mote hypersensitivity. , 1973, Journal of immunology.

[10]  J. Km,et al.  Epizootiology of Venezuelan equine encephalomyelitis in the Americas. , 1972 .

[11]  C. E. Pedersen,et al.  Isolation of the vaccine strain of Venezuelan equine encephalomyelitis virus from mosquitoes in Louisiana. , 1972, American journal of epidemiology.

[12]  K. Johnson,et al.  Experimental Infection of Horses with an Attenuated Venezuelan Equine Encephalomyelitis Vaccine (Strain TC-83) , 1972, Infection and immunity.

[13]  W. Reeves,et al.  Field Studies of an Attenuated Venezuelan Equine Encephalomyelitis Vaccine (Strain TC-83) , 1972, Infection and immunity.

[14]  T. Duffy,et al.  An inactivated eastern equine encephalomyelitis vaccine propagated in chick-embryo cell culture. II. Clinical and serologic responses in man. , 1970, The American journal of tropical medicine and hygiene.

[15]  R. Williams,et al.  Differences in anti-protein A activity among IgG subgroups. , 1969, Journal of immunology.

[16]  N. A. Young,et al.  Antigenic variants of Venezuelan equine encephalitis virus: their geographic distribution and epidemiologic significance. , 1969, American journal of epidemiology.

[17]  R. Feigin,et al.  Live, attenuated Venezuelan equine encephalomyelitis virus vaccine. I. Clinical effects in man. , 1967, The American journal of tropical medicine and hygiene.

[18]  G. R. French,et al.  USE OF BETA-PROPIOLACTONE IN PREPARATION OF INACTIVATED ARBOVIRUS SEROLOGIC TEST ANTIGENS. , 1964, Journal of immunology.

[19]  R. Mckinney,et al.  USE OF AN ATTENUATED STRAIN OF VENEZUELAN EQUINE ENCEPHALOMYELITIS VIRUS FOR IMMUNIZATION IN MAN. , 1963, The American journal of tropical medicine and hygiene.

[20]  W. D. Tigertt,et al.  ATTENUATION OF VENEZUELAN EQUINE ENCEPHALOMYELITIS VIRUS BY IN VITRO CULTIVATION IN GUINEA-PIG HEART CELLS , 1961 .

[21]  J. Casals,et al.  Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses. , 1958, The American journal of tropical medicine and hygiene.

[22]  D. G. Smith,et al.  Venezulean equine encephalomyelitis; laboratory aspects of fourteen human cases following vaccination and attempts to isolate the virus from the vaccine. , 1956, American journal of hygiene.

[23]  K. Kuttler,et al.  Immunization of laboratory workers with purified trivalent equine encephalomyelitis vaccine. , 1952, Journal of immunology.

[24]  J. Mills,et al.  The preparation and properties of a purified equine encephalomyelitis vaccine. , 1947, Journal of immunology.

[25]  T. Jones,et al.  The Development of Foreign Protein Sensitization in Human Beings , 1936, The Journal of Immunology.

[26]  T. Jones,et al.  The Phases of Foreign Protein Sensitization in Human Beings , 1934 .